A 6-month, multicenter, open-label evaluation of beaded, extended-release carbamazepine capsule monotherapy in bipolar disorder patients with manic or mixed episodes.

@article{Ketter2004A6M,
  title={A 6-month, multicenter, open-label evaluation of beaded, extended-release carbamazepine capsule monotherapy in bipolar disorder patients with manic or mixed episodes.},
  author={Terence A. Ketter and Amir H. Kalali and Richard H. Weisler},
  journal={The Journal of clinical psychiatry},
  year={2004},
  volume={65 5},
  pages={668-73}
}
BACKGROUND Carbamazepine is frequently used for treating bipolar disorder, but few large trials have assessed its efficacy in preventing relapse. We evaluated open-label monotherapy with beaded extended-release carbamazepine capsules (ERC-CBZ; SPD417) as continuation and short-term maintenance therapy in bipolar disorder patients with manic and mixed episodes. METHOD A 6-month, open-label study enrolled 92 patients with DSM-IV bipolar disorder (most recent episode: 67% [N = 62] mixed, 33% [N… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 14 extracted citations

Pharmacological treatment of mixed states.

CNS spectrums • 2017
View 4 Excerpts
Highly Influenced

The World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Biological Treatment of Bipolar Disorders: Acute and long-term treatment of mixed states in bipolar disorder.

The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry • 2018
View 2 Excerpts
Highly Influenced

Olanzapine plus carbamazepine v. carbamazepine alone in treating manic episodes.

The British journal of psychiatry : the journal of mental science • 2008

Similar Papers

Loading similar papers…